This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Gerd Gross, MD
University-Hospital Eppendorf Hamburg, Germany for the Recombinant Interferon-Gamma in Condylomata Acuminata Study Group

JAMA. 1991;266(19):2706.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

— Recent studies have shown that genital warts can be effectively treated with interferon administered intralesionally.^1-3 This approach is not ideal since untreated lesions do not respond and pain at the injection site may limit the use of this route of administration to treat multiple lesions, which are a common clinical presentation of genital human papillomavirus infection.

However, using a systemic approach, a recent international multicenter trial,⁴ which used subcutaneous injections of recombinant interferon alfa-2a in daily doses of 3.0 mIU or 9.0 mIU three times weekly for 4 weeks, failed to demonstrate the superiority of any of the two interferon groups over the placebo group (response rates of 34% or 25%, respectively, vs 30%).

In contrast, low-dose treatment with 1.5 mIU of recombinant interferon alfa-2a, which was given cyclically (daily therapy for consecutive days followed by a therapy-free interval of 4 weeks), seemed to . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?